4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Agios Pharmaceuticals, Inc. (AGIO) operates in the Biotechnology industry and is headquartered in Cambridge, United States with about 539 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, AGIO reported $54M in revenue and ($413M) in net income.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Interactive charts & full statements → Open the AGIO valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $54M | $36M | $27M | $14M | — |
| Gross Profit | $48M | $32M | $24M | $12M | — |
| Operating Income (EBIT) | ($472M) | ($426M) | ($392M) | ($389M) | — |
| Net Income | ($413M) | $674M | ($352M) | ($232M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $21M | $20M | $13M | $12M | $9M | — |
| Gross Profit | $19M | $18M | $11M | $11M | $8M | — |
| Operating Income (EBIT) | ($110M) | ($122M) | ($117M) | ($127M) | ($107M) | — |
| Net Income | ($99M) | ($108M) | ($103M) | ($112M) | ($89M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $1.3B | $1.7B | $937M | $1.2B | — |
| Total Liabilities | $104M | $122M | $126M | $138M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AGIO viewer.
About TickerBase · Data methodology & sources